The Lucile Packard Children's Hospital aims to improve health through leadership, diversity, and collaborative discoveries and innovation in health care, education and research.
The Bass Center for Childhood Cancer and Blood Diseases, which is ranked by the U.S. News & World Report and part of the Stanford Cancer Institute, an NCI-designated comprehensive cancer center, aims to help young people with pediatric cancer and blood diseases manage or overcome their medical conditions. With a fully integrated inpatient/outpatient environment and a world-class faculty and staff, the Bass Center provides an ideal environment for delivering the best possible care for children, adolescents, and young adults with blood diseases and cancer. The center is designed to create a hopeful, healing environment by moving most services for cancer and blood diseases to one physical location in the hospital, expediting care delivery and ensuring optimal care coordination. The Bass Center includes inpatient facilities, a clinic, an onsite laboratory, a fully equipped day hospital, a procedure unit with general anesthesia capability and a specialized pharmacy. Alongside this, the Bass Center also has dedicated research programs in cancer, blood diseases, stem cell transplantation (SCT) and regenerative medicine.
The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) was founded in February 2003 by Dr. Tanya Trippett at Memorial Sloan-Kettering Cancer Center and Dr. Lia Gore at the University of Colorado Cancer Center to address the challenges of access of new therapies for children with cancer that has recurred. The initial administrative office, POETIC Data Coordinating Center (DCC), was located at Memorial Sloan Kettering, NY.
The POETIC RDMC (formerly known as POETIC DCC) transitioned to the Pediatric Hematology Oncology at Stanford University in 2019, under the direction of Dr. Norman Lacayo.
The consortium has evolved over 16 years from a clinical trials network to a research business enterprise with a strong research infrastructure that drives the development of innovative therapeutic strategies based upon the biology of the patient’s cancer.
Research Team
Norman Lacayo, MD received his BA in Biochemistry from UC Berkeley, and his MD from UC San Francisco School of Medicine (UCSF). He completed his residency in Pediatrics at UCSF and fellowship in Pediatric Hematology/Oncology/Stem Cell Transplantation at Stanford University. Dr. Lacayo is currently an Associate Professor of Pediatrics, a member of the Stanford Cancer Institute, and Lucile Packard Children's Hospital Stanford (LPCHS). At LPCHS he is the Co-Director of the Leukemia Program and Interim Oncology Section Leader. Dr. Lacayo's research focuses on the discovery and evaluation of new biomarkers in childhood acute leukemia. He actively collaborates with the Children's Oncology Group, led the ADVL0114 study using Decitabine for relapse and refractory leukemia, and is currently a member of the COG Myeloid Committee. Also participated in the St. Jude AML Consortium Trials AML02, AML08 and AML16. Dr. Lacayo became the first institutional PI for the Pediatric Oncology Experimental Therapies Investigational Consortium (POETIC) group in October 2015.
"Our institution and POETIC consortium provide a nurturing environment that makes collaboration easy, and quickly brings new therapies for children at all our sites."
Allie Pribnow, MD, MPH received her BA in Spanish Foreign Language & Literature from Whitman College, her MPH from Oregon State University, and her MD from Oregon Health & Sciences University (OHSU). She completed her residency training in Pediatrics at Stanford University and her fellowship in Pediatric Hematology/Oncology at St. Jude Children’s Research Hospital. Dr. Pribnow is currently a Clinical Assistant Professor at Stanford University and an attending physician at Lucile Packard Children’s Hospital Stanford (LPCHS). She is the physician lead of the Chemotherapy Safety Committee and a member of the Hematology/Oncology/SCT Professional Practice Evaluation Committee. Dr. Pribnow currently serves as the COG Adolescent and Young Adult (AYA) Responsible Investigator for the LPCHS site. She has a clinical concentration in solid tumors with a focus on management of bone sarcomas.Her academic interests include treatment of recurrent/refractory OS and EWS, AYA oncology and global oncology.